Search results
Found 6777 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Using data to improve transfusion practice
We will develop a fully linked electronic system from blood donor to patient, allowing us to monitor and improve the use of blood.
Clinical adoption and market access
You have now identified what your intellectual property strategy would look like, how to integrate it with your regulatory strategy and the technical development of your device. Your project development phase is progressing well and you have started the prototyping phase of your device. How can you now facilitate the transition from R&D phase to its clinical adoption and make sure your device will ultimately be used in the clinics? Our experts in residence from Odelle Technology, Deborah Rizzi, Dr Steven Haken and Claire Edwards have provided key principles that you can implement in the development phase to eliminate roadblocks to facilitate the clinical adoption of your device.
NAVIGATING INTELLECTUAL PROPERTY STRATEGY AND INVESTMENT
In this section, we will explore how you can develop your medical device so that your intellectual property strategy becomes a true asset, not a just cost, driving your project to its next step. We will discuss how investors, or companies, will look at your data, where the value of your project lies, may that be in patent, design rights or trademarks, and what components will attract investments and collaborative opportunities. Intellectual Property is a core part of any business and despite being an intangible assets has utility in many forms including; as a commercial asset, a tool from which to build and can be utilised to protect commercial value and competitive position.
Exploring the commercial opportunity of developing a medical device
You may have an idea for a medical device which is original, technically feasible and serves an unmet medical need. Unfortunately, that does not guarantee that it will be a commercially viable product. In this section, Dr Nessa Carey, Royal Society Entrepreneur in Residence at the University of Oxford, will utilise a real case study to explore the key commercial questions you need to address very early in the translation of your device idea. Here we present a case study-based exploration of key questions, led by Dr Nessa Carey, Royal Society Entrepreneur in Residence at the University of Oxford
Validation of an early biomarker of Alzheimers disease using diffusion imaging or cortical microstructure.
Transcript of an interview with Dr Steven Chance
Experts in Residence: Two Years in the Making
The Translational Research Office (TRO) has released a new brochure to highlight the success of their Experts in Residence programme.
Advanced Bioscience of Viral Products
The CTP in Advanced Bioscience of Viral Products (ABViP) is a 4-year, comprehensive, multidisciplinary training programme designed and led by gene and cell therapy company Oxford Biomedica in collaboration with the University of Oxford and University College London. The programme aims to deliver the next generation of bioscience leaders to advance research on the underpinning bioscience of viral products for future gene therapies and vaccines.
Sixty Seconds with Dr Simon Warner
Dr Simon Warner is Head of Licensing & Ventures - Life Sciences at Oxford University Innovation (OUI). Simon has over twenty-five years’ experience in commercial Biotechnology in various roles, raising venture capital, securing strategic partners and philanthropic funding sources. We talk to Simon about his career to date, his role at OUI, and his passion for seeing innovative ideas and inventions make it to real life.
Sixty Seconds with Stephen Woodley
Stephen Woodley joined Biomedical Services (BMS) last October as Head of Research Delivery. In this role, Stephen is responsible for the function within BMS, providing care and welfare of animals within research. The role is also responsible for supporting researchers, in particular with procedural support offered by the department. In this Sixty Seconds interview, we hear from Stephen about his career to date, what a typical day is like for him and about his passion for animal welfare.